Posted: September 27, 2014 at 1:46 am
Dr. Daniel Kuebler: Stem Cell Research
Dr. Daniel Kuebler, Professor of Biology at Franciscan University of Steubenville and author of "The Evolution Controversy", discusses the controversial topi...
By: Franciscan University of Steubenville
Read the rest here:
Dr. Daniel Kuebler: Stem Cell Research - Video
Posted: September 27, 2014 at 1:46 am
JSB Market Research: Stem Cell Research Products - Opportunities, Tools, and Technologies
Stem cells are still a relatively new discovery, as the first mouse embryonic stem cells were derived from embryos in 1981, but it was not until 1995 that th...
By: Rahul Shinde
Visit link:
JSB Market Research: Stem Cell Research Products - Opportunities, Tools, and Technologies - Video
Posted: September 26, 2014 at 12:57 am
Looking for help with Diarrhoea in Colfax? Listed below are doctors and medical centers in and near Colfax North Dakota.
If you are not looking for help with Diarrhoea, check out the popular Diarrhoea info on the right navigation area of the page. On the Diarrhoea pages we include website links so you can check out Diarrhoea online.
Are you searching for information about Diarrhoea? Have you or someone you know been diagnosed with Diarrhoea? Have you considered Stem Cell treatments for Diarrhoea? Welcome to the stem cell center service for the state of KY! Many diseases and illnesses don't have to be as treacherous as once thought. There are potential cures and treatments available that are quite effective and very hopeful for Diarrhoea If you are ready to consider adult stem cell treatment and adult stem cell therapy as an alternative for your medical disorder Diarrhoea, then you are at the right place. Here at alternativetreatmentsfor.com we specialize in providing effective stem cells for Diarrhoea in or near Colfax, KY 95713. For immediate, free, and confidential assistance, download or .pdf file and call our helpline NOW!
Are you searching for a stem cell? Have you or someone you know been diagnosed with Diarrhoea ? Welcome to the stem cell center service for the state of North Dakota! Many diseases and illnesses are more treatable than most people once thought. There are many potential cures - stem cells and treatments available that have proven to be quite effective and very hopeful for Diarrhoea
If you are open to the idea of adult stem cell treatment and adult stem cell therapy as an alternative method of treatment for your medical disorder Diarrhoea, then you have found the right place. Here at naturalcurefor.com we specialize in helping people heal by providing effective and stem cells for Diarrhoea in or near Colfax, North Dakota 95713. For immediate, free, and confidential assistance, download our .pdf file and call our helpline NOW!
We have successfully helped many people in North Dakota. We can help you attain real, effective, stem cells and alternative treatments for Diarrhoea. Health improvements after our natural method of treatments have been used have shown terrific results in a very high percentage of cases. Every human being deserves to have good health and that is our desire to sincerely provide a network of resources available to help you or your loved one achieve better health. Don't let another day or week go by. Don't think that the pain or the Diarrhoea you or a loved one have endured cannot be ended or put on a better more natural healing path to good health. Don't give up hope. We can help you recover, but you have to take the first step by contacting us now!
Colfax, North Dakota - Stem cell for Diarrhoea - We Can Provide Some Tremendous Hope if You Are Willing to Consider Adult Stem Cell Therapy and Treatments as Your Path Back To Good Health
Treating Diarrhoea in a traditional medical manner is sometimes a long and grueling process that can offer less hope than you deserve. Additionally, many traditional medical treatments are riddled with drugs and medications that can sometimes cause even more harm to other parts of the body. Further risks of medication mixups, allergies, destruction of the immune system and the constant level of additional medical treatments that may be required, can sometimes weigh heavily on a patient and their chances of regaining a healthful way of life. Recovery can become difficult or almost impossible in some cases.
We offer an alternative treatment or a more stem cell process that centers around the idea of using your own adult stem cells as the basis of this natural treatment. In some areas of the country, traditional medicine and medical practices may not have acknowledged the benefits that stem cell treatments can bring to the healing process. Stem cell treatments may not be a standard course of medical treatment quite yet, but that may be a result of other political and/or profit motives. But rest assured that is all changing and changing quite rapidly as more and more success and overwhelming evidence indicates that adult stem cell therapy is a very successful and viable treatment process for Diarrhoea.
Stem cell treatment is extremely effective and very safe. It is also very natural, ethical and a very effective way in assisting the body to heal naturally and wholesomely. It embodies the very idea of "healing" rather than simply medicating a symptom. The main idea of how adult stem cell treatments work are as follows...
Continued here:
Stem Cell Therapy for Diarrhoea in Colfax North Dakota
Posted: September 26, 2014 at 12:52 am
Overview of Cancer Immunotherapy
The immune system deals with cells and organisms that express foreign antigens by a process of antigen presentation to T cells then communication with B cells. This is followed by the production of cytotoxic T cells that can recognize antigens, and the production by differentiated B cells of antibodies that target those antigens. The system also has a memory process so that if an antigen is seen again, the immune response is mobilized even faster. T cells are capable of killing tumor cells. However, there are feedback mechanisms in many diseases, particularly cancer, that can turn off and/or repress the processes of antigen recognition and immune response.
Some experts have suggested that within 10 years, 60% of cancers will be treated with immunotherapy (Nature, Vol. 508, 3 April 2014). Immune responses can be induced and/or enhanced by vaccination using a single or handful of well-characterized tumor antigens. Injections of exogenously expanded cytotoxic T cells that recognize a single antigen on a patients cancer have been shown to eliminate metastatic disease in a subset of patients. However, cancers do not express a single antigen. Further, it is now known that most of these mutations are unique to that patients cancer; so it is not surprising that approaches that have involved immunization with only one or a few antigens, or injections of someone elses cultured tumor cells have not been successful.
We believe that a better approach would involve a broader array of antigens and would utilize the patients own tumor, also known as autologous tumor. A number of those methods that have been tried have sought to draw antigens from an entire tumor mass. However, the cells of interest are the cancer stem cells or replicating cells, those with indefinite multiplicative capability. Only a few of those cells are present in the tumor mass, perhaps as few as 1/100,000 cells have this potential. Moreover, the tumor mass by definition includes a variety of other cells, such as immune cells, blood cells and other cells, some or many of which may inhibit or otherwise interfere with antigen recognition.
NeoStems approach is different in two fundamental ways from other autologous therapies: (i) it presents to the patients immune system the entire spectrum of antigens from that patients own tumor and (ii) it separates out and re-administers just those cells from the patients tumor that are self-renewing, that is, those that can regenerate the cancer and cause metastatic spread against which an immune response is most needed. Those cells are pretreated with radiation and are connected to a dendritic cell to optimize presentation to the T cell.
Basic and clinical research have established that in some patients there is the ability to recognize tumor antigens, but as a result of their disease there are mechanisms that interfere with this process, while other patients have an existing immune recognition of tumor antigens, but their immune response is being suppressed. This is the basis for the new monoclonal antibody therapies such as anti-CTLA4, anti-PD-1, and anti-PD-L1 that are providing clinical benefit in the setting of metastatic melanoma. These so-called checkpoint inhibitors, i.e., drugs that block checkpoint proteins, work by either stimulating an existing immune response to tumor antigens, or liberating a repressed immune response to tumor antigens. However, their mechanisms of action rely on pre-existing recognition of tumor antigens by the immune system. NeoStems approach is different in that it is designed to induce or enhance recognition of all the tumor antigens expressed on the tumors self-renewing cells. In other words, the therapys intent is to increase the target specifically, its self-renewing stem cells.
The lead candidate in the program is the Companys DC/TC (dendritic cell/tumor cell) product*, a treatment for malignant melanoma. In a Phase 2 randomized clinical trial of subcutaneously injected DC/TC,DC/TC improved two year overall survival in patients with advanced melanoma (recurrent Stage III or Stage IV) to 72% compared to 31% for control patients treated with only their own tumor cells suspended in granulocyte macrophage colony stimulating factor (GM-CSF) (p=0.007). The toxicity profile was favorable with no grade IV and only one grade III (allergic reaction) event in the study. The allergic reaction was attributed to the granulocyte macrophage colony-stimulating factor (GMCSF), an FDA-approved immune stimulant used in the final drug formulation. There were no other significant toxicities seen in either an earlier single-arm Phase 2 trial or this randomized Phase 2 trial. Local injection site reactions, such as skin irritation and itching, did occur, but the symptoms dissipated within hours after the injection. There were no significant adverse effects on hematopoietic cells or renal function, liver function, or patient performance status. View Phase 2 trial results.
NeoStems immunotherapeutic approach is a platform technology that NeoStem believes could be expanded into other indications, such as hepatocellular carcinoma and other immune responsive tumor types.
* NeoStem has submitted a United States Adopted Names Council application for the Companys DC/TC product for metastatic melanoma to use the generic name Melapuldencel-T.
Continue reading here:
California Stem Cell, Inc.
Posted: September 26, 2014 at 12:51 am
Postdoctoral Fellow
The Bo Liu laboratory: Vascular Biology Research Laboratory
An NIH funded postdoctoral position is available immediately in a Vascular Biology Research Laboratory of University of Wisconsin, Madison to investigate pathophysiology of a vascular disease called abdominal aortic aneurysm. The incumbent is expected to use mouse models of aneurysm as well as 2D- and 3-D cell cultures to study how extracellular matrix proteins influence vascular inflammation. Ph.D. or M.D./Ph.D. in cell biology, physiology, or related biomedical fields are required. Experiences in transgenic mice, mouse survival surgery, and immunohistology are desired.
Please send curriculum vitae to:Bo Liu, Ph.D. at liub @surgery.wisc.edu
Postdoctoral Fellow
The David Gamm laboratory at the Waisman Center, University of Wisconsin-Madison is seeking a postdoctoral fellow to work on funded projects involving derivation of retinal cell types from human embryonic stem (ES) and induced pluripotent stem (iPS) cells for use as models of human retinal development and disease. For more information about specific research interests and current projects, see http://stemcells.wisc.edu/node/158
A PhD background in genetics, molecular biology or cell biology is preferred. Additional experience in vision sciences, physiology, developmental biology, and/or stem cell biology would be advantageous, although not required.
Interested candidates should e-mail a cover letter and a copy of their current CV to: Dr. David Gamm at dgamm@wisc.edu Lynda Wright at wright@waisman.wisc.edu
Research Associate (Postdoctoral)
Department of Surgery and McPherson Eye Research Institute
Read the rest here:
Career Opportunities | Stem Cell and Regenerative Medicine ...
Posted: September 26, 2014 at 12:44 am
Contact Information
Available for logged-in reporters only
Newswise Columbus, OH. Premature babies face a host of medical challenges at birth, but none as deadly and mysterious as a disease called necrotizing enterocolitis (NEC). The condition creates an inexplicable combination of inflammation and infection that causes parts of the intestine to die. NEC progresses at a ruthless speed, leaving physicians with few options typically supportive care, emergency surgery or antibiotics. Only half of newborns who undergo surgery survive, and they often face serious life-long complications.
In the fifty years since necrotizing enterocolitis was first identified, weve accomplished relatively little to change its devastating course. Even worse, we dont know which babies will get it. One minute, a child can appear healthy, but then be dead from NEC hours later, said Gail Besner, MD, chief of pediatric surgery at Nationwide Childrens Hospital.
That may be about to change thanks to two major breakthroughs driven by Besner and Surgeon-in-Chief at Nationwide Childrens R. Lawrence Moss, MD.
After nearly two decades of work, their separate efforts have yielded both the discovery of a biomarker that can help predict which babies will get the disease, as well as treatments that can restore the intestines natural ability to protect itself against NEC.
These researchers advances offer innovative approaches to necrotizing enterocolitis that may someday make it a more predictable and better managed complication of prematurity, said John Barnard, MD, President of the Nationwide Childrens Research Institute and Pediatric Director of The Ohio State University Center for Clinical and Translational Science (CCTS).
Growth factors, stem cells offer gut protection For Besner, the key has always been to prevent NEC before it can start. In the 1990s, she began looking closely at what was happening at the molecular level to an immature bowel in the throes NEC. Besner made a major discovery, observing that a protein called heparin-binding EGF-like growth factor (HB-EGF) which she initially discovered played a life and death role in protecting premature infants from NEC.
In numerous studies, Besner showed that without HB-EGF, the structures within the intestines that maintain barrier function and integrity, including a massive network of nerves and blood vessels, became easily injured and beyond repair. The addition of HB-EGF had the opposite effect, helping protect intestines from injury in animal models of NEC.
From that molecular level understanding of NEC, Besner developed a bigger picture hypothesis about how the nerve damage within an immature gut impacted the diseases development and progression and where a solution might be found.
Continued here:
Biomarkers, Stem Cells Offer New Ways to Treat Deadly Gut Disease in Premature Babies
Posted: September 25, 2014 at 7:47 pm
What is a Stem Cells?
What is a Stem Cells? More Info ://l1nk.com/StemCells.
By: Jeunesse Secret
Originally posted here:
What is a Stem Cells? - Video
Posted: September 25, 2014 at 7:47 pm
Knee Stem Cell Injections
Knee Stem Cell Injections can be a treatment for chronic pain such as Avascular Necrosis as a means of non-surgical treatment as opposed to surgery. Stem Cell Injections for Knee Osteoarthritis...
By: Dr. Lox
Read more:
Knee Stem Cell Injections - Video
Posted: September 25, 2014 at 3:46 pm
Over 500 million people worldwide carry a genetic mutation that disables a common metabolic protein called ALDH2. The mutation, which predominantly occurs in people of East Asian descent, leads to an increased risk of heart disease and poorer outcomes after a heart attack. It also causes facial flushing when carriers drink alcohol.
Now researchers at the Stanford University School of Medicine have learned for the first time specifically how the mutation affects heart health. They did so by comparing heart muscle cells made from induced pluripotent stem cells, or iPS cells, from people with the mutation versus those without the mutation. IPS cells are created in the laboratory from specialized adult cells like skin. They are "pluripotent," meaning they can be coaxed to become any cell in the body.
"This study is one of the first to show that we can use iPS cells to study ethnic-specific differences among populations," said Joseph Wu, MD, PhD, director of the Stanford Cardiovascular Institute and professor of cardiovascular medicine and of radiology.
"These findings may help us discover new therapeutic paths for heart disease for carriers of this mutation," said Wu. "In the future, I believe we will have banks of iPS cells generated from many different ethnic groups. Drug companies or clinicians can then compare how members of different ethnic groups respond to drugs or diseases, or study how one group might differ from another, or tailor specific drugs to fit particular groups."
The findings are described in a paper that will be published Sept. 24 in Science Translational Medicine. Wu and Daria Mochly-Rosen, PhD, professor of chemical and systems biology, are co-senior authors of the paper, and postdoctoral scholar Antje Ebert, PhD, is the lead author.
ALDH2 and cell death
The study showed that the ALDH2 mutation affects heart health by controlling the survival decisions cells make during times of stress. It is the first time ALDH2, which is involved in many common metabolic processes in cells of all types, has been shown to play a role in cell survival. In particular, ALDH2 activity, or the lack of it, influences whether a cell enters a state of programmed cell death called apoptosis in response to stressful growing conditions.
The use of heart muscle cells derived from iPS cells has opened important doors for scientists because tissue samples can be easily obtained and maintained in the laboratory for study. Until recently, researchers had to confine their studies to genetically engineered mice or to human heart cells obtained through a heart biopsy, an invasive procedure that yields cells which are difficult to keep alive long term in the laboratory.
"People have studied the enzyme ALDH2 for many years in animal models," said Ebert. "But there are many significant differences between mice and humans. Now we can study actual human heart muscle cells, conveniently grown in the lab."
The iPS cells in this study were created from skin samples donated by 10 men, ages 21-22, of East Asian descent.
Read more here:
Stem cells used to learn how common mutation in Asians affects heart health
Posted: September 25, 2014 at 3:46 pm
Updated: 09/24/2014 10:46 PM Created: 09/24/2014 5:24 PM WNYT.com By: WNYT Staff
RENSSELAER - Middle school students from Robert C. Parker School in North Greenbush took a field trip to the Neural Stem Cell Institute at UAlbany's east campus to learn about themselves on a cellular level.
This is a unique school trip as these middle school students are getting a hands on lesson in the ABCs of cutting edge biology - the role stem cells play in our lives.
Well, I learned that cells make up all of your body, said Shy'Leah Riggsbee, a 7th grader.
In partnership with the Neural Stem Cell institute the middle schoolers at the Robert C. Parker School spend a day in the lab. Since stem cells are increasingly being used to develop new treatments it's the perfect place to immerse the next generation of scientists.
So, by the time these children are going to decide on their careers we're going to have a lot of new therapies hitting the market. It'll be booming. So this is a great time to introduce them to stem cells as a career choice, said Dr. Chris Fasano with NSCI
Woven into this science lesson is a mini math lesson - the measuring of testing fluids - observing reaction times, and reliance on technology to develop the tools and protocols needed to mine the mysteries of how stem cell technology can affect our health.
For middle school kids, theres nothing more motivating than helping solve real problems, said Meg Taylor, head of school. They want to make a difference in the world.
I really want to learn about it in more depth now, because it's so cool and interesting, said Sophia Arnold, a 6th Grader.
If you've got a STEM story you would like to share, e-mailstem13@wnyt.com.
